BioMedNewsBreaks

ThursdayJun 04, 2026 10:15 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Drug-Delivery Market Growth

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining growing investor interest in platform biotech companies as the global drug-delivery market advances toward an estimated $410 billion opportunity. The editorial highlights increasing industry focus on overcoming challenges related to drug penetration, tumor targeting, therapeutic resistance and maintaining consistent intratumoral exposure, while spotlighting Oncotelic’s Sapu003 and Deciparticle platform as examples of nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance. To view the full press release, visit  https://ibn.fm/laaQ6 About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical…

Continue Reading

WednesdayJun 03, 2026 2:00 pm

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) CEO to Present at Planet MicroCap Las Vegas 2026 Investor Conference

Earth Science Tech (OTC: ETST) announced that Chief Executive Officer and Chairman Giorgio R. Saumat will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026, at the Bellagio Resort & Hotel in Las Vegas. The presentation will include a live question-and-answer session with attendees. Earth Science Tech, Inc. (OTC: ETST) also said management will be available throughout the conference for in-person, one-on-one meetings with investors. To view the full press release, visit https://ibn.fm/7PQxd About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness…

Continue Reading

WednesdayJun 03, 2026 12:48 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Sapu003 Phase 1b Program, Appoints Global CRO for International Study Execution

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. The move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe. SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The company said GCT…

Continue Reading

WednesdayJun 03, 2026 12:39 pm

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances Kilogram-Scale Manufacturing for ONC010 Program 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in the development of ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology. Conducted through its chemistry, manufacturing and controls collaboration with Dalton Pharma Services, the effort resulted in the production and isolation of approximately 952 grams of B4 material, supporting future formulation development, GMP production and planned clinical studies. The company said the manufacturing milestone strengthens its integrated development strategy and supports the establishment of a scalable production…

Continue Reading

WednesdayJun 03, 2026 12:23 pm

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Expands Patent Portfolio with Ebola Triage Application

VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company's existing Nu.Q(R) NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality. Volition said its CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. The company is seeking partnerships with global health organizations, pharmaceutical developers, NGOs and distribution partners to support field…

Continue Reading

WednesdayJun 03, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial exploring how biotechnology companies are increasingly leveraging advanced drug-delivery technologies, nanotechnology platforms and artificial intelligence to enhance existing therapies and expand treatment opportunities. The article highlights Oncotelic’s Sapu003 program, Deciparticle(TM) platform and PDAOAI initiative as part of a broader industry trend toward scalable, multi-application biotechnology platforms capable of supporting oncology and rare disease programs. The editorial also discusses developments from CytoDyn Inc. (OTCQB: CYDY), which is advancing leronlimab for oncology indications; Revolution Medicines Inc. (NASDAQ: RVMD), which reported positive Phase 3 results for daraxonrasib in pancreatic cancer; Moderna Inc. (NASDAQ:…

Continue Reading

TuesdayJun 02, 2026 2:39 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how biotechnology companies are increasingly focusing on advanced drug delivery technologies to enhance the effectiveness of existing cancer therapies. The article highlights growing industry interest in nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic approaches designed to improve bioavailability, systemic exposure, tolerability and dosing consistency. The editorial notes that Oncotelic is advancing its Sapu003 program and Deciparticle(TM) platform as part of a broader trend toward nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy focuses on developing platform technologies with potential applications across multiple oncology and rare disease indications rather than relying on a single therapeutic…

Continue Reading

TuesdayJun 02, 2026 1:24 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, announced that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC beginning June 8, 2026. Under the six-month agreement, the agency will provide services including company profile creation, media distribution, digital community development, news marketing and lead generation campaigns for a fee of US$250,000. Quantum said IR Agency LLC is arm’s-length to the company and holds no direct or indirect equity interest in its securities.  To view the full press release,…

Continue Reading

TuesdayJun 02, 2026 12:54 pm

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product 

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with additional product from the production run designated for upcoming clinical research in the United States and clinical trials in Europe. The company said all stages of manufacturing were completed in-house at its Health Canada-licensed facility, including biomass cultivation, active pharmaceutical ingredient extraction, encapsulation and packaging. Optimi said its vertically integrated platform…

Continue Reading

TuesdayJun 02, 2026 10:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data showing that LP-300, in combination with carboplatin and pemetrexed, demonstrated a progression-free survival benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following TKI therapy. The emerging data showed a median progression-free survival of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort, while maintaining what the company described as an exceptionally clean safety and tolerability profile, supporting a recently FDA-cleared protocol…

Continue Reading